Synergistic rifabutin and colistin reduce emergence of resistance when treating Acinetobacter baumannii.

Synergistic rifabutin and colistin reduce emergence of resistance when treating Acinetobacter baumannii.
Antimicrob Agents Chemother. 2021 Jan 19;:
Authors: Cheng J, Yan J, Reyna Z, Slarve M, Lu P, Spellberg B, Luna B
Abstract
Recently, we reported rifabutin hyper-activity against Acinetobacter baumannii We sought to characterize potential interactions between rifabutin and colistin, the last resort drug for carbapenem-resistant infections. Rifabutin and colistin were synergistic in vitro and in vivo, and low dose colistin significantly suppressed emergence of resistance to rifabutin. Thus, this combination is a promising therapeutic option for highly resistant A. baumannii infections.
PMID: 33468472 [PubMed - as supplied by publisher]

Source: Antimicrobial Agents and Chemotherapy - January 19, 2021 Category: Microbiology Authors: Cheng J, Yan J, Reyna Z, Slarve M, Lu P, Spellberg B, Luna B Tags: Antimicrob Agents Chemother Source Type: research